Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants by Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, Harsh Jogdand, Dugyala Raju, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Kumar Rai, Raches Ella, Priya Abraham, Sai Prasad, Krishna Ella

Get full text

A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India by Raghu Reddy, Bhargav Reddy, Vamshi Sarangi, Siddharth Reddy, Raches Ella, Krishna Mohan Vadrevu

Get full text

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®) by Chandramani Singh, Savita Verma, Prabhakar Reddy, Michael S. Diamond, David T. Curiel, Chintan Patel, Manish Kumar Jain, Sagar Vivek Redkar, Amit Suresh Bhate, Vivek Gundappa, Rambabu Konatham, Leelabati Toppo, Aniket Chandrakant Joshi, Jitendra Singh Kushwaha, Ajit Pratap Singh, Shilpa Bawankule, Raches Ella, Sai Prasad, Brunda Ganneru, Siddharth Reddy Chiteti, Sreenivas Kataram, Krishna Mohan Vadrevu

Get full text

Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority compa... by Krishna Kumari P, Siddharth Reddy Chiteti, Vinay K. Aileni, Sudhir Babji, William C. Blackwelder, Ashok Kumar, Jayant Vagha, Uma Nayak, Monjori Mitra, Narayanaappa D, Sonali Kar, Sangeeta Yadav, Swamy Naidu, Niranjan Mahantshetti, Vasant Khalatkar, Satyajit Mohapatra, P. K. Purthi, Pawan Sharma, A. Kannan, Ramchandra Keshav Dhongade, Sai D. Prasad, Raches Ella, Krishna Mohan Vadrevu

Get full text

A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simult... by Raches Ella, Radhika Bobba, Sanjay Muralidhar, Sudhir Babji, Krishna Mohan Vadrevu, Maharaj Kishan Bhan

Get full text

Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate Vaccines by Fang Gao, Kay Lockyer, Alastair Logan, Sarah Davis, Barbara Bolgiano, Sjoerd Rijpkema, Gopal Singh, Sai D. Prasad, Samuel Pradeep Dondapati, Gurbaksh Singh Sounkhla

“…Studies performed in parallel by the vaccine manufacturer, Bharat Biotech International Limited, and an independent national control laboratory (NIBSC) monitored its stability-indicating parameters: <i>O</i>-acetylation of the Vi polysaccharide, integrity of the polysaccharide–protein conjugate, and its molecular size and pH. …”
Get full text

Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella va... by Krishna Mohan Vadrevu, Raju Dugyala, Niranjana Shamulinga Mahantashetti, Vasant Khalatkar, Krishna Murthy, Sandeep Mogre, Monjori Mitra

Get full text

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model by Pragya D. Yadav, Sreelekshmy Mohandas, Anita Shete, Gajanan Sapkal, Gururaj Deshpande, Abhimanyu Kumar, Kundan Wakchaure, Hitesh Dighe, Rajlaxmi Jain, Brunda Ganneru, Jyoti Yemul, Pranita Gawande, Krishna Mohan Vadrevu, Priya Abraham

Get full text

Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases by Velayudhan Mohan Kumar, Seithikurippu R. Pandi-Perumal, Ilya Trakht, Sadras Panchatcharam Thyagarajan

“…India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. …”
Get full text

ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial by Temsunaro Rongsen Chandola, Sunita Taneja, Nidhi Goyal, Kalpana Antony, Kiran Bhatia, Deepak More, Nita Bhandari, Iksung Cho, Krishna Mohan, Sai Prasad, GVJA Harshavardhan, Tataji Surender Rao, Sudhanshu Vrati, Maharaj Kishan Bhan

Get full text

Ethnological aspects of COVID-19 by Priya Dhiman, Meenakshi Bhatia

“…Some of the recently approved vaccines are developed by Pfizer and Moderna, Johnson and Johnson, Gam-COVID-vac (Sputnik V), Bharat Biotech (covaxin) andOxford-AstraZeneca vaccines (covishield) (Badenet al., 2021). …”
Get full text

Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1 by Annika Skansberg, Molly Sauer, Marissa Tan, Mathuram Santosham, Mary Carol Jennings

“…In addition to the globally available, WHO-prequalified ROTARIX (GSK) and RotaTeq (Merck), several new rotavirus vaccines have attained national licensure – ROTAVAC (Bharat Biotech) and ROTASIIL (Serum Institute of India), licensed and manufactured in India and now WHO-prequalified, and Rotavin-M1 (PolyVac), licensed and manufactured in Vietnam. …”
Get full text

Spectrum of mucocutaneous reactions to COVID-19 vaccination: A report from a web-based study from India by Abheek Sil, Deepak Jakhar, Anupam Das, Soumya Jagadeesan, Sujala Sacchidanand Aradhya

“…Methods: An online questionnaire-based study was performed among the recipients of COVID-19 vaccines Results: Majority (73.6%) of the responders had received the Covishield vaccine (AstraZeneca-Oxford), while 26.4% had been vaccinated with Covaxin (Bharat Biotech-ICMR). One or more post-vaccination mucocutaneous effects were experienced in 87 (19.6%) participants. …”
Get full text

Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax; a Systematic Review by Omid Dadras, Esmaeil Mehraeen, Amirali Karimi, Marcarious M. Tantuoyir, Arian Afzalian, Newsha Nazarian, Hengameh Mojdeganlou, Pegah Mirzapour, Ahmadreza Shamsabadi, Mohsen Dashti, Afsaneh Ghasemzadeh, Farzin Vahedi, Parnian Shobeiri, Zahra Pashaei, SeyedAhmad SeyedAlinaghi

“…Conclusion: This systematic review indicates that inactivated COVID-19 vaccines, including Sinovac, Sinopharm, and Bharat Biotech, as well as the protein subunit vaccines (Novavax) can be considered as safe choices due to having milder side effects and fewer severe life-threatening adverse events. …”
Get full text

Study on adverse event following COVID 19 vaccination at tertiary care hospital, Karwars by Kolur Ashwini M., Kushalabharathi Vishwaprakash M., Havale Naveen Kumar G., Naik Harish G.

“…Covaxin, an inactivated vaccine developed and manufactured by Bharat Biotech and Covishield, the Oxford AstraZeneca vaccine is being manufactured locally by Serum Institute of India. …”
Get full text

Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines by Sheila Isanaka, Andrew Clark, Clint Pecenka, Kevin Tang, Rebecca F Grais, Bachir Assao, Frédéric Debellut, Ousmane Guindo

“…Local data were collected as part of a clinical trial taking place in the Madarounfa district, Maradi region, Niger.Participants The study models impact of infants vaccination on rotavirus gastroenteritis in children under 5 years of age.Interventions We compared the use of ROTARIX (GlaxoSmithKline, Belgium), ROTAVAC (Bharat Biotech, India) and ROTASIIL (Serum Institute, India) to no vaccination and to each other over a 10-year period starting in 2021.Results We estimated that ROTARIX, ROTAVAC and ROTASIIL would each prevent 13 million cases and 20 000 deaths of children under 5 years over a 10-year period in Niger. …”
Get full text

VACCINATION COVERAGE AMONG HEALTH CARE WORKER IN A GOVERNMENT CANCER HOSPITAL IN EASTERN UTTAR PRADESH IN INDIA by M. Gupta, S. Singh

“…Two vaccines used for this drive were Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin. Our institute an upcoming state of art cancer centre in eastern Uttar Pradesh and acted as a centre for vaccination. …”
Get full text

A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM197 co... by Subhash Thuluva, Vikram Paradkar, Ramesh Matur, Kishore Turaga, Subba Reddy GV

“…We conducted a multicenter, single-blind, randomized, Phase 2/3 study to assess the immunogenicity and safety of Biological E’s Typhoid Vi-CRM197 conjugate vaccine (TyphiBEVTM) compared to Vi-TT conjugate vaccine manufactured by Bharat Biotech International Limited (Typbar-TCV; licensed comparator) in healthy infants, children, and adults from India. …”
Get full text

Human health implications of emerging diseases and the current situation in India's vaccine industry by Jiban Kumar Behera, Pabitra Mishra, Anway Kumar Jena, Bhaskar Behera, Manojit Bhattacharya

“…India's vaccine sector has emerged, among the oriented leaders of the Bharat Biotech, Serum Institute of India, Panacea Biotech and Biological E. …”
Get full text

Vaccination is the most effective and best way to avoid the disease of COVID‐19 by Hadi Lotfi, Mina G. Mazar, Negar M. H. Ei, Mostafa Fahim, Nafiseh S. Yazdi

“…Among the inactive viral vaccines, the following can be mentioned: CoronaVac (Sinovac) WIBP vaccine (Wuhan Institute of Biological Products, Sinopharm), BBIBPCorV (Beijing Institute of Biological Products, Sinopharm), BBV152/Covaxin (Bharat Biotech, ICMR, National Institute of Virology) And among the protein‐based/subunit vaccines, the following can be counted: NVX‐CoV2373: (Novavax); SCB‐2019 vaccine (Clover Biopharmaceuticals AUS Pty Ltd.); Covax‐19 (GeneCure Biotechnologies; Vaxine Pty Ltd.) mRNA vaccines, viral vector vaccines, and protein subunit vaccines cannot cause disease because these vaccines stimulate the immune system to produce antibodies against virus proteins instead of the virus itself (or its antigen). …”
Get full text